| MEK3 Protein | |
|---|---|
| Protein Name | MEK3 Protein |
| Gene Symbol | MAP2K3 |
| UniProt ID | P46734 |
| PDB Structures | 3MGC, 3MGD |
| Molecular Weight | 38 kDa |
| Subcellular Localization | Cytoplasm |
| Protein Family | MAP Kinase Kinase Family |
MEK3 is a protein involved in cellular signaling and transcriptional regulation.[1] This protein plays important roles in regulating gene expression and cellular signaling.[2] In the context of neurodegenerative diseases, MEK3 is implicated in Alzheimer's disease, Parkinson's disease, and other disorders through various mechanisms.[3]
MAP2K3 (MEK3) has a typical protein kinase structure with an N-terminal regulatory region and a C-terminal kinase domain. It contains a dual-specificity protein kinase domain that phosphorylates both tyrosine and threonine residues on its substrates. The protein has a docking motif (D-motif) for interaction with MAP kinases. Activation loop phosphorylation at Ser218 and Thr222 is required for activity.
MAP2K3 (MEK3) is a dual-specificity protein kinase that activates p38 MAP kinase signaling pathways. It phosphorylates and activates MAP kinase 14 (p38-alpha), MAP kinase 11 (p38-beta), and MAP kinase 12 (p38-gamma). MAP2K3 is activated by cellular stresses including oxidative stress, inflammatory cytokines, and UV radiation. It plays roles in cell proliferation, differentiation, apoptosis, and inflammatory responses. The MAP2K3/p38 pathway is a key stress-activated signaling cascade.
The MAP2K3/p38 pathway is heavily implicated in neurodegenerative diseases. In Alzheimer's disease, p38 activation is found in neurons around amyloid plaques, contributing to tau phosphorylation, synaptic dysfunction, and neuroinflammation. In Parkinson's disease, MAP2K3/p38 signaling promotes dopaminergic neuron death in response to oxidative stress. In ALS, p38 activation in motor neurons and glia contributes to neuroinflammation. This pathway represents a therapeutic target for neurodegeneration.
MAP2K3/p38 inhibitors have been extensively explored as anti-inflammatory and neuroprotective agents. SB203580 and SB239063 are p38 inhibitors that have shown neuroprotective effects in animal models. However, clinical trials for p38 inhibitors have been disappointing due to side effects and lack of efficacy. Newer approaches include targeting upstream MAP2K3 or downstream p38 isoforms. Targeting specific cell types may improve therapeutic outcomes.